GSK Reports Strong Q4 Performance with Positive 2026 Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 04 2026
0mins
Should l Buy GSK?
Source: NASDAQ.COM
- Significant Profit Growth: GSK's pre-tax profit surged to £950 million in Q4 from £563 million last year, demonstrating strong performance in Specialty Medicines, which is expected to drive continued growth in future earnings.
- Steady Revenue Increase: The company's Q4 revenue rose 6.2% year-over-year to £8.618 billion, reflecting double-digit sales growth in Respiratory, Immunology & Inflammation, Oncology, and HIV, enhancing its competitive position in the market.
- Optimistic Future Outlook: GSK projects core earnings per share and core operating profit growth of 7% to 9% for fiscal 2026, with turnover expected to increase by 3% to 5%, indicating strategic decisions focused on ongoing R&D and commercialization investments.
- Increased Dividends: The company declared an increased dividend of 18 pence per share for Q4, with an expected 70 pence per share for 2026, reflecting strong business performance and commitment to shareholder returns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GSK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GSK
Wall Street analysts forecast GSK stock price to fall
6 Analyst Rating
1 Buy
2 Hold
3 Sell
Moderate Sell
Current: 58.540
Low
20.15
Averages
38.72
High
55.60
Current: 58.540
Low
20.15
Averages
38.72
High
55.60
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GSK Set to Trade Ex-Dividend; Dividend Sustainability Analysis
- Ex-Dividend Date Approaching: GSK's stock will trade ex-dividend on February 19, meaning investors purchasing after this date will miss the £0.18 per share dividend payable on April 9, which is crucial for dividend-seeking investors.
- Stable Dividend Yield: Last year, GSK paid a total dividend of £0.72 per share against a current share price of £21.65, resulting in a 3.3% yield, indicating stability in dividend payments despite limited future growth potential.
- Moderate Payout Ratio: With a payout ratio of 47%, GSK's dividends are supported by profits, and last year's dividends consumed 53% of free cash flow, suggesting a sustainable payment capability.
- Weak Earnings Growth: While earnings per share have grown at an average rate of 3.1% annually over the past five years, dividends have declined by an average of 3.2% per year over the last decade, indicating challenges in dividend growth that may affect long-term investor confidence.
See More
Moderna Exceeds Q4 Sales Expectations, 2026 Growth Outlook Positive
- Sales Performance Exceeds Expectations: Moderna's Q4 sales surpassed market expectations, with specific figures undisclosed, indicating strong performance in the vaccine market and boosting investor confidence.
- Positive Growth Outlook: The company maintains an optimistic growth outlook for 2026, anticipating continued benefits from increased vaccine demand, particularly in emerging markets, which could drive long-term revenue growth.
- Regulatory Challenges: However, the FDA's refusal of Moderna's flu vaccine application raises concerns about the company's vaccine product line, potentially impacting future sales forecasts.
- Market Reaction: Despite facing regulatory challenges, Moderna's overall performance remains robust, and investors should monitor how the company addresses FDA feedback and the progress of future vaccine development.
See More
Moderna Reports Q4 Earnings Beat Expectations
- Earnings Highlights: Moderna reported a Q4 loss of $2.11, beating the expected loss of $2.59 and improving from a loss of $2.91 a year ago, indicating effective cost control measures.
- Sales Performance: Quarterly sales reached $678 million, exceeding expectations of $626 million, with $264 million from the U.S. and $381 million from international markets, although down 30% year-over-year, reflecting ongoing demand for COVID vaccines.
- Future Outlook: Moderna targets up to 10% revenue growth in 2025, with a revenue split of approximately 50% from the U.S. and 50% from international markets in 2026, highlighting the company's focus on international expansion potential.
- FDA Challenge: Moderna faced a setback with the FDA's refusal-to-file letter for its influenza vaccine mRNA-1010, which analysts believe poses a significant threat to the company's vaccine franchise and could hinder its path to breakeven by 2028, reflecting challenges in the regulatory environment.
See More
FENI Price Fluctuation Analysis and ETF Dynamics
- Price Fluctuation Range: FENI's 52-week low is $26.2144 per share, with a high of $40.47, and the last trade at $40.31 indicates the stock is fluctuating near its high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and identify potential buy or sell opportunities.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets and market trends.
See More
GSK's RSV Vaccine Application Accepted in China
- Regulatory Progress: GSK announced that China's Center for Drug Evaluation has accepted its regulatory application for the RSV vaccine Arexvy, marking the official start of the review process, and if approved, it will provide the first RSV vaccine for adults aged 60 and older, significantly enhancing health protection for this demographic.
- Market Demand Potential: The Arexvy vaccine aims to prevent lower respiratory tract disease caused by respiratory syncytial virus, and given the serious impact of RSV on the elderly, its launch will meet the urgent market need for respiratory disease prevention in older adults, potentially leading to substantial market revenue.
- Technological Innovation: The vaccine combines recombinant RSV glycoprotein F with GSK's proprietary AS01E adjuvant to form a stabilized prefusion conformation, showcasing GSK's technological prowess in vaccine development and further solidifying its leadership position in the biopharmaceutical industry.
- Stock Performance: GSK's shares have risen for seven consecutive trading sessions, reflecting positive market sentiment regarding its vaccine development progress, and if Arexvy is approved, it is expected to further drive stock price increases and enhance investor confidence.
See More
GSK's Nucala Approved by EU for COPD Treatment
- Drug Approval: GSK announced that its biologic Nucala has been approved by the European Commission as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD), marking a significant advancement in the company's respiratory disease portfolio.
- Clinical Trial Results: This approval is based on the Phase III MATINEE trial results, where Nucala demonstrated a clinically meaningful and statistically significant reduction in the annualized rate of moderate to severe COPD exacerbations compared to placebo.
- Market Potential: COPD affects over 390 million people globally, including around 40 million in Europe, and the approval of Nucala is expected to provide GSK with substantial revenue growth opportunities in this large market.
- Stock Price Reaction: Following the announcement, GSK shares rose by 3.39% to close at $59.17, reflecting the market's positive expectations regarding the drug's potential commercial value.
See More
GSK Set to Trade Ex-Dividend; Dividend Sustainability Analysis
- Ex-Dividend Date Approaching: GSK's stock will trade ex-dividend on February 19, meaning investors purchasing after this date will miss the £0.18 per share dividend payable on April 9, which is crucial for dividend-seeking investors.
- Stable Dividend Yield: Last year, GSK paid a total dividend of £0.72 per share against a current share price of £21.65, resulting in a 3.3% yield, indicating stability in dividend payments despite limited future growth potential.
- Moderate Payout Ratio: With a payout ratio of 47%, GSK's dividends are supported by profits, and last year's dividends consumed 53% of free cash flow, suggesting a sustainable payment capability.
- Weak Earnings Growth: While earnings per share have grown at an average rate of 3.1% annually over the past five years, dividends have declined by an average of 3.2% per year over the last decade, indicating challenges in dividend growth that may affect long-term investor confidence.
See More
Moderna Exceeds Q4 Sales Expectations, 2026 Growth Outlook Positive
- Sales Performance Exceeds Expectations: Moderna's Q4 sales surpassed market expectations, with specific figures undisclosed, indicating strong performance in the vaccine market and boosting investor confidence.
- Positive Growth Outlook: The company maintains an optimistic growth outlook for 2026, anticipating continued benefits from increased vaccine demand, particularly in emerging markets, which could drive long-term revenue growth.
- Regulatory Challenges: However, the FDA's refusal of Moderna's flu vaccine application raises concerns about the company's vaccine product line, potentially impacting future sales forecasts.
- Market Reaction: Despite facing regulatory challenges, Moderna's overall performance remains robust, and investors should monitor how the company addresses FDA feedback and the progress of future vaccine development.
See More
Moderna Reports Q4 Earnings Beat Expectations
- Earnings Highlights: Moderna reported a Q4 loss of $2.11, beating the expected loss of $2.59 and improving from a loss of $2.91 a year ago, indicating effective cost control measures.
- Sales Performance: Quarterly sales reached $678 million, exceeding expectations of $626 million, with $264 million from the U.S. and $381 million from international markets, although down 30% year-over-year, reflecting ongoing demand for COVID vaccines.
- Future Outlook: Moderna targets up to 10% revenue growth in 2025, with a revenue split of approximately 50% from the U.S. and 50% from international markets in 2026, highlighting the company's focus on international expansion potential.
- FDA Challenge: Moderna faced a setback with the FDA's refusal-to-file letter for its influenza vaccine mRNA-1010, which analysts believe poses a significant threat to the company's vaccine franchise and could hinder its path to breakeven by 2028, reflecting challenges in the regulatory environment.
See More
FENI Price Fluctuation Analysis and ETF Dynamics
- Price Fluctuation Range: FENI's 52-week low is $26.2144 per share, with a high of $40.47, and the last trade at $40.31 indicates the stock is fluctuating near its high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and identify potential buy or sell opportunities.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets and market trends.
See More
GSK's RSV Vaccine Application Accepted in China
- Regulatory Progress: GSK announced that China's Center for Drug Evaluation has accepted its regulatory application for the RSV vaccine Arexvy, marking the official start of the review process, and if approved, it will provide the first RSV vaccine for adults aged 60 and older, significantly enhancing health protection for this demographic.
- Market Demand Potential: The Arexvy vaccine aims to prevent lower respiratory tract disease caused by respiratory syncytial virus, and given the serious impact of RSV on the elderly, its launch will meet the urgent market need for respiratory disease prevention in older adults, potentially leading to substantial market revenue.
- Technological Innovation: The vaccine combines recombinant RSV glycoprotein F with GSK's proprietary AS01E adjuvant to form a stabilized prefusion conformation, showcasing GSK's technological prowess in vaccine development and further solidifying its leadership position in the biopharmaceutical industry.
- Stock Performance: GSK's shares have risen for seven consecutive trading sessions, reflecting positive market sentiment regarding its vaccine development progress, and if Arexvy is approved, it is expected to further drive stock price increases and enhance investor confidence.
See More
GSK's Nucala Approved by EU for COPD Treatment
- Drug Approval: GSK announced that its biologic Nucala has been approved by the European Commission as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD), marking a significant advancement in the company's respiratory disease portfolio.
- Clinical Trial Results: This approval is based on the Phase III MATINEE trial results, where Nucala demonstrated a clinically meaningful and statistically significant reduction in the annualized rate of moderate to severe COPD exacerbations compared to placebo.
- Market Potential: COPD affects over 390 million people globally, including around 40 million in Europe, and the approval of Nucala is expected to provide GSK with substantial revenue growth opportunities in this large market.
- Stock Price Reaction: Following the announcement, GSK shares rose by 3.39% to close at $59.17, reflecting the market's positive expectations regarding the drug's potential commercial value.
See More
